Eli Lilly and Company (NYSE:LLY) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Eli Lilly and Company (NYSE:LLY) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

A number of other analysts have also weighed in on LLY. BMO Capital Markets upped their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a research report on Monday, October 20th. Morgan Stanley cut their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a research report on Friday, October 3rd. Daiwa Capital Markets lowered Eli Lilly and Company from an “outperform” rating to a “neutral” rating and set a $700.00 price objective on the stock. in a research report on Sunday, August 17th. Guggenheim reaffirmed a “buy” rating and set a $948.00 price objective on shares of Eli Lilly and Company in a research report on Thursday, October 16th. Finally, DZ Bank raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Thursday, August 14th. One analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have assigned a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Stock Up 3.9%

Shares of NYSE LLY opened at $896.15 on Friday. The firm has a market cap of $848.17 billion, a price-to-earnings ratio of 58.57, a PEG ratio of 1.21 and a beta of 0.47. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $935.63. The business’s 50 day moving average is $784.74 and its two-hundred day moving average is $772.35.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Thursday, October 30th. The company reported $7.02 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.42 by $0.60. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The company had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. During the same quarter in the previous year, the company earned $1.18 earnings per share. The firm’s quarterly revenue was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is 29.35%.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, Director Jamere Jackson bought 200 shares of the company’s stock in a transaction that occurred on Friday, August 8th. The shares were purchased at an average price of $639.56 per share, with a total value of $127,912.00. Following the completion of the acquisition, the director directly owned 9,402 shares of the company’s stock, valued at $6,013,143.12. This represents a 2.17% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Daniel Skovronsky bought 1,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president directly owned 137,660 shares of the company’s stock, valued at $87,331,504. The trade was a 0.73% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 4,514 shares of company stock valued at $2,894,841 over the last ninety days. Company insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Large investors have recently bought and sold shares of the stock. Lazard Freres Gestion S.A.S. lifted its position in shares of Eli Lilly and Company by 114.3% during the 2nd quarter. Lazard Freres Gestion S.A.S. now owns 77,295 shares of the company’s stock valued at $60,253,000 after acquiring an additional 41,222 shares during the period. Precedent Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 15.3% during the 2nd quarter. Precedent Wealth Partners LLC now owns 294 shares of the company’s stock valued at $229,000 after acquiring an additional 39 shares during the period. Capital Advisors Inc. OK lifted its position in shares of Eli Lilly and Company by 6.8% during the 2nd quarter. Capital Advisors Inc. OK now owns 6,747 shares of the company’s stock valued at $5,260,000 after acquiring an additional 429 shares during the period. Family CFO Inc acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth approximately $54,000. Finally, Duquesne Family Office LLC raised its position in shares of Eli Lilly and Company by 52.5% during the 1st quarter. Duquesne Family Office LLC now owns 94,830 shares of the company’s stock worth $78,321,000 after purchasing an additional 32,640 shares during the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.